ALX Oncology (NASDAQ: ALXO) insider transactions
In the twelve months to 10 November 2026, executives and directors of ALX Oncology reported 7 open-market sales of 21,911 shares ($42,588) and 1 open-market purchase of 3,184,713 shares ($5.0m), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 17 August 2026 | Wong Shelly | SVP, Finance and CAO | Open-market sale | −573 | $1.93 | 87,828 | Form 4 |
| 17 August 2026 | Lettmann Jason | Chief Executive Officer | Open-market sale | −2,230 | $1.93 | 294,379 | Form 4 |
| 1 July 2026 | Wong Shelly | SVP, Finance and CAO | Open-market sale | −1,404 | $2.04 | 88,401 | Form 4 |
| 19 March 2026 | Pinto Shelly | SVP, Finance and CAO | Open-market sale | −903 | $2.17 | 86,805 | Form 4 |
| 19 March 2026 | Lettmann Jason | Chief Executive Officer | Open-market sale | −12,311 | $2.17 | 293,609 | Form 4 |
| 18 February 2026 | Pinto Shelly | SVP, Finance and CAO | Open-market sale | −565 | $2.27 | 87,708 | Form 4 |
| 17 February 2026 | Lettmann Jason | Chief Executive Officer | Shares withheld for tax | −2,201 | $2.27 | 305,920 | Form 4 |
| 2 February 2026 | Goodman Corey S | Director | Open-market purchase | +3,184,713 | $1.57 | 8,453,038 | Form 4 |
| 6 January 2026 | Pinto Shelly | SVP, Finance and CAO | Open-market sale | −3,925 | $1.11 | 88,273 | Form 4 |
| 17 September 2025 | Lettmann Jason | Chief Executive Officer | Open-market purchase | +71,163 | $1.08 | 305,121 | Form 4 |
| 16 September 2025 | Lettmann Jason | Chief Executive Officer | Open-market purchase | +21,070 | $1.07 | 233,958 | Form 4 |
| 18 August 2025 | Shantharam Harish | Chief Financial Officer | Open-market purchase | +75,000 | $0.78 | 75,000 | Form 4 |
| 15 August 2025 | Lettmann Jason | Chief Executive Officer | Open-market sale | −2,382 | $0.64 | 212,888 | Form 4 |
| 15 August 2025 | Pinto Shelly | SVP, Finance and CAO | Open-market sale | −611 | $0.64 | 89,198 | Form 4 |
| 7 July 2025 | Pinto Shelly | SVP, Finance and CAO | Open-market sale | −2,011 | $0.45 | 86,809 | Form 4 |
| 30 June 2025 | Pinto Shelly | SVP, Finance and CAO | Open-market sale | −1,532 | $0.43 | 88,820 | Form 4 |
| 14 March 2025 | Lettmann Jason | Chief Executive Officer | Grant or award | +42,000 | — | 212,270 | Form 4 |
| 14 March 2025 | Pinto Shelly | SVP, Finance and CAO | Grant or award | +3,000 | — | 90,352 | Form 4 |
| 19 February 2025 | Lettmann Jason | Chief Executive Officer | Open-market sale | −2,159 | $1.15 | 170,270 | Form 4 |
| 19 February 2025 | Pons Jaume | President & Cso | Open-market sale | −1,326 | $1.15 | 579,388 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the ALX Oncology page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.